Serum and in vitro production of IL-1 receptor antagonist correlate with C-reactive protein levels in newly diagnosed, untreated lupus patients

Clinical and Experimental Rheumatology

Volumn 19, Issue 5, 2001, Pages 515-523

  Liou, L B ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

Author keywords

CRP; IL 1 ra; Monocytes; Untreated lupus

Indexed keywords

BIOLOGICAL MARKER; C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLASMA PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CELL SECRETION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DATA ANALYSIS; DISEASE ACTIVITY; DISEASE ASSOCIATION; EXPERIMENTATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKOCYTE CULTURE; MALE; MONOCYTE; NEUTROPHIL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RHEUMATOID ARTHRITIS; SERODIAGNOSIS; SERUM; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; AGED; ARTHRITIS, RHEUMATOID; C-REACTIVE PROTEIN; CELLS, CULTURED; FEMALE; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; INTERLEUKIN-1; INTERLEUKIN-6; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; MONOCYTES; SEVERITY OF ILLNESS INDEX; SIALOGLYCOPROTEINS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0034837757     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. Clinical presentation of systemic lupus erythematosus
2. Clinical features of rheumatoid arthritis
3. Immunologic factors and clinical activity in lupus erythematosus
4. Relationship between erythrocyte sedimentation rate and serum C-reactive protein in rheumatoid arthritis
5. C-reactive protein in systemic lupus erythematosus
6. C-reactive protein levels during disease exacerbations and infections in systemic lupus erythematosus: A prospective longitudinal study
7. The acute phase response
8. Regulation of hepatic acute phase plasma protein genes by hepatocyte stimulating factors and other mediators of inflammation
9. Elevated levels of endogenous IL-6 in systemic lupus erythematosus. A putative role in pathogenesis
10. Impaired tumor necrosis factor-alpha (TNF-α) production and abnormal B cell response to TNF-α in patients with systemic lupus erythematosus
11. Profiles of cytokines (TNF-α and IL-6) and acute phase proteins (CRP and alpha 1AG) related to the disease in patients with systemic lupus erythematosus
12. Interleukin-6 (IL-6) and acute phase proteins in the disease course of patients with systemic lupus erythematosus
13. Plasma concentration of IL-6 in systemic lupus erythematosus; an indicator of disease activity ?
14. Glucocorticoids inhibit the production of IL-6 from monocytes, endothelial cells and fibroblasts
15. The Th1 and Th2 cytokines IFN-gamma and IL-4 antagonize the inhibition of monocyte IL-1 receptor antagonist by glucocorticoids: Involvement of IL-1
16. Soluble cytokine receptors: Their role in immunoregulation
17. Blocking IL-1: Effects of IL-1 receptor antagonist in vitro and in vivo
18. Biology of multifunctional cytokines: IL-6 and related molecules (IL-1 and TNF)
19. The major acute phase proteins: C-reactive protein, serum amyloid P component and serum amyloid A protein
20. Derivation of the SLEDAI. A disease activity index for lupus patients
21. Preparation of human mononuclear cell populations and subpopulations
22. Isolation of monocyte and macrophage populations
23. Human monocytes produce IL-1 and an inhibitor of IL-1 in response to two different signals
24. Increased TNF-α secretion by alveolar macrophages from patients with rheumatoid arthritis
25. Involvement of protein kinase C and protein tyrosine kinase in lipopolysaccharide-induced TNF-α and IL-1β production by human monocytes
26. Increased spontaneous production of interleukin-6 by peripheral mononuclear cells in patients with rheumatoid arthritis
27. Naturally occurring inhibitors of cytokines
28. Absence of correlation between interleukin-6 and C-reactive protein blood levels in systemic lupus erythematosus compared with rheumatoid arthritis
29. Observations on the interleukin-6 and acute phase protein profiles in the disease course of patients with lupus erythematosus
30. Biological properties of recombinant human monocyte-derived interleukin-1 receptor antagonist
31. Interleukin-1 receptor antagonist in patients with active systemic lupus erythematosus. Enhanced production by monocytes and correlation with disease activity
32. Low levels of interleukin-1 receptor antagonist coincide with kidney involvement in systemic lupus erythematosus
33. Correlation of serum measures of nitric oxide production with lupus disease activity
34. Circadian characteristics of circulating interleukin-6 in man
35. Expression of interleukin-1β, tumor necrosis factor α, interleukin-6, -10 and -4, and metalloproteases by freshly isolated mononuclear cells from early never-treated and non-acute treated rheumatoid arthritis patients
36. Interleukin-10 and interleukin-6 in lupus erythematosus and rheumatoid arthritis, correlations with acute phase proteins
37. Serum concentrations of interleukin 6, osteocalcin, intact parathyroid hormone, and markers of bone resorption in patients with rheumatoid arthritis
38. IL-1 receptor antagonist (IL-1Ra) does not inhibit the production of C-reactive protein or serum amyloid A protein by human primary hepatocytes. Differential regulation in normal and tumour cells
39. Anti-inflammatory properties of hepatic acute phase proteins: Preferential induction of interleukin-1 (IL-1) receptor antagonist over IL-1β synthesis by human peripheral blood mononuclear cells
40. Interleukin 1 receptor antagonist (IL-1Ra) is an acute-phase protein